

Educational Sessions

Wednesday, 10 October 2018

08.00 – 09.30 **Educational Session 1: Pregnancy management in MS** Hall D

Level: Basic

Chairs:

K. Hellwig (Bochum, DE)

A. Langer Gould (Pasadena, US)

08.00 **Symptomatic MS treatment and pregnancy / lactation management**

M. Magyari (Copenhagen, DK)

08.30 **The natural history of MS during pregnancy and the postpartum period in contemporary MS cohorts**

A. Langer Gould (Pasadena, US)

09.00 **MS medication in people with MS planning a pregnancy - an update**

K. Hellwig (Bochum, DE)

08.00 – 09.30 **Educational Session 2: Practical treatment recommendations based on new guidelines in MS** Hall E

Level: Basic

Chairs:

X. Montalban (Barcelona, ES)

D. Pelletier (Los Angeles, US)

Detailed programme to be announced

08.00 – 09.30 **Educational Session 3: Neurofilament light chains in MS: where do we stand, the long road to clinical application** Hall F

Level: Intermediate

Chairs:

C. Teunissen (Amsterdam, NL)

J. Kuhle (Basel, CH)

08.00 **The long road to clinical application: where do we stand with neurofilament light chain in MS?**

J. Kuhle (Basel, CH)

08.30 **The long road to clinical implementation**

C. Teunissen (Amsterdam, NL)

09.00 **Clinical application today and tomorrow**

F. Piehl (Stockholm, SE)

08.00 – 09.30	Educational Session 4: Immunology of MS Level: Advanced Chairs: <i>E. Meinl (Martinsried, DE)</i> <i>V.W.W. Yong (Calgary, CA)</i>	Hall H
08.00	B and T cells in MS <i>E. Meinl (Martinsried, DE)</i>	
08.30	Myeloid cells in MS <i>V.W.W. Yong (Calgary, CA)</i>	
09.00	Systems immunology to model, predict, and monitor MS <i>C. Farina (Milan, IT)</i>	

08.00 – 09.30	Educational Session 5: Impact and management of comorbidities in MS Level: Intermediate Chairs: <i>R.A. Marrie (Winnipeg, CA)</i> <i>H. Tremlett (Vancouver, CA)</i>	Hall G
08.00	Impact of comorbidity in MS <i>R.A. Marrie (Winnipeg, CA)</i>	
08.30	Bidirectional relationships between comorbidity and disease-modifying therapy <i>H. Tremlett (Vancouver, CA)</i>	
09.00	Management of psychiatric comorbidity in MS <i>A. Feinstein (Toronto, CA)</i>	

09.45 – 10.30	Case-based Educational Session 6: How to manage non-response to highly active (second line) drugs? Chairs: <i>A.J. Coles (Cambridge, UK)</i> <i>J. Sastre-Garriga (Barcelona, ES)</i>	Hall F
09.45	Case 1 <i>A.J. Coles (Cambridge, UK)</i>	
10.07	Case 2 <i>J. Sastre-Garriga (Barcelona, ES)</i>	

09.45 – 10.30	Case-based Educational Session 7: Progressive MS: who should be treated and how to monitor treatment response?	Hall G
	Chairs: <i>B.A.C. Cree (San Francisco, US)</i> <i>R. Kapoor (London, UK)</i>	
09.45	Case 1 <i>B.A.C. Cree (San Francisco, US)</i>	
10.07	Case 2 <i>R. Kapoor (London, UK)</i>	
<hr/>		
09.45 – 10.30	Case-based Educational Session 8: Should all MS patients be treated?	Hall H
	Chairs: <i>A. Chan (Bern, CH)</i> <i>M. Stangel (Hannover, DE)</i>	
09.45	Pro <i>M. Stangel (Hannover, DE)</i>	
10.07	Con <i>A. Chan (Bern, CH)</i>	
<hr/>		
13.30 – 15.00	Educational Session 9: Clinical trials in MS: the need for novelty	Hall F
	Level: Advanced Chairs: <i>M.P. Sormani (Genoa, IT)</i> <i>J. Chataway (London, UK)</i>	
13.30	Endpoints in MS clinical trials: going beyond EDSS <i>F. Pellegrini (Zug, CH)</i>	
14.00	More flexibility for future MS trials: adaptive designs <i>J. Chataway (London, UK)</i>	
14.30	Prognosis, response to therapy and treatment effect: easy to say, hard to measure <i>M.P. Sormani (Genoa, IT)</i>	
<hr/>		

-
- 13.30 – 15.00 **Educational Session 10: Innovation in MRI in relation to cognitive and neuropsychiatric phenomena in MS (IMSCOGS)** Hall G
Level: Advanced
Chairs:
C. Enzinger (Graz, AT)
- 13.30 **Neuropathological injury in MS and relationship to structural MRI metrics**
J. Geurts (Amsterdam, NL)
- 14.00 **Functional MRI studies in MS: update on brain plasticity and repair**
C. Enzinger (Graz, AT)
- 14.30 **Functional relevance of MRI in early MS, correlation with cognitive performance and related outcomes**
B. Brochet (Bordeaux, FR)
-
- 13.30 – 15.00 **Educational Session 11: Molecular mechanisms of tissue injury in cortical MS lesions** Hall H
Level: Advanced
Chairs:
J. Van Horssen (Amsterdam, NL)
D.J. Mahad (Edinburgh, UK)
- 13.30 **Unraveling the cause of neuronal mitochondrial dysfunction in MS**
J. Van Horssen (Amsterdam, NL)
- 14.00 **Uncovering the pathogenesis of synapse loss in cortical MS and its models**
M. Kerschensteiner (Munich, DE)
- 14.30 **Understanding the early clinical and pathological consequences of mitochondrial dysfunction in progressive MS**
D.J. Mahad (Edinburgh, UK)
-
- 15.30 – 17.00 **Educational Session 12: MS mimicks: other neuro-inflammatory disorders** Hall F
Level: Basic
Chairs:
D.M. Wingerchuk (Scottsdale, US)
A. Siva (Istanbul, TR)
M. Keegan (Rochester, US)
- 15.30 **NMOSD and related autoantibody CNS Disorders**
A. Siva (Istanbul, TR)
- 16.00 **Atypical inflammatory syndromes of the CNS**
M. Keegan (Rochester, US)
- 16.30 **Primary and secondary inflammatory vasculopathies and other inflammatory disorders of the CNS mimicking MS**
C. Rice (Bristol, UK)

15.30 – 17.00	Educational Session 13: Genetics and biomarkers in MS	Hall G
	Level: Advanced	
	Chairs: <i>B. Hemmer (Munich, DE)</i> <i>M. Comabella (Barcelona, ES)</i>	
15.30	General considerations in biomarker research and application <i>B. Hemmer (Munich, DE)</i>	
16.00	Serum and CSF biomarkers in MS <i>M. Comabella (Barcelona, ES)</i>	
16.30	Basics of MS genetics <i>S.E. Baranzini (San Francisco, US)</i>	

15.30 – 17.00	Educational Session 14: Myelin repair in MS	Hall H
	Level: Advanced	
	Chairs: <i>C. Lubetzki (Paris, FR)</i>	
15.30	What have we learnt on remyelination in MS? an historical perspective <i>C. Lubetzki (Paris, FR)</i>	
16.00	Promoting exogenous remyelination: from basic sciences to translation <i>S. Goldman (Copenhagen, DK)</i>	
16.30	Promoting endogenous remyelination: from basic sciences to trans <i>A. Green (San Francisco, US)</i>	

Thursday, 11 October 2018

- 08.00 – 09.30 **Educational Session 15: Disease modifying treatments in MS** Hall D
Level: Basic
Chairs:
H.-P. Hartung (Düsseldorf, DE)
T. Derfuss (Basel, CH)
- 08.00 **Disease modifying treatments for relapsing MS**
H.-P. Hartung (Düsseldorf, DE)
- 08.30 **Treatment approaches to progressive MS**
T. Derfuss (Basel, CH)
- 09.00 **Risks, risk management, and the choice of treatments for MS**
G. Giovannoni (London, UK)
-

- 08.00 – 09.30 **Educational Session 16: Symptomatic treatment of MS:
how to manage pain/bladder/bowel/sexual dysfunction? (RIMS)** Hall E
Level: Basic
Chairs:
P.L. Eelen (Melsbroek, BE)
R. Moss Morris (London, UK)
- 08.00 **Management of bladder and bowel problems**
P.L. Eelen (Melsbroek, BE)
- 08.30 **Treatment of sexual dysfunction**
C.A. Young (Liverpool, UK)
- 09.00 **Pain management**
R. Moss Morris (London, UK)
-

- 10.00 – 11.30 **Educational Session 17: MS pathology for clinical neurologists** Hall D
Level: Basic
Chairs:
W. Brück (Göttingen, DE)
C. Stadelmann (Göttingen, DE)
- 10.00 **The white matter lesion in MS**
W. Brück (Göttingen, DE)
- 10.30 **The grey matter lesion in MS**
C. Stadelmann (Göttingen, DE)
- 11.00 **Inflammatory demyelination spectrum**
R. Höftberger (Vienna, AT)

10.00 – 11.30	Educational Session 18: Experimental neuroimmunology	Hall E
	Level: Advanced	
	Chairs: <i>A. Flügel (Göttingen, DE)</i> <i>T. Kuhlmann (Münster, DE)</i>	
10.00	Immunopathogenesis in CNS autoimmunity: lessons from animal models <i>A. Flügel (Göttingen, DE)</i>	
10.30	Experimental MS models and their relation to the human disease <i>T. Kuhlmann (Münster, DE)</i>	
11.00	Blood-brain barrier autoimmune function and dysfunction in CNS autoimmunity <i>B. Engelhardt (Bern, CH)</i>	
<hr/>		
11.45 – 12.45	Case-based Educational Session 19: Pediatric MS	Hall E
	Chairs: <i>T. Chitnis (Boston, US)</i> <i>J. Gärtner (Göttingen, DE)</i>	
11.45	What's in a name? Pediatric MS or another diagnosis? <i>T. Chitnis (Boston, US)</i>	
12.15	Treatment of highly active pediatric MS and potential treatment failures <i>J. Gärtner (Göttingen, DE)</i>	
<hr/>		
14.15 – 15.45	Educational Session 20: MRI and the diagnosis of multiple sclerosis (MAGNIMS)	Hall D
	Level: Basic	
	Chairs: <i>F. Barkhof (London, UK)</i> <i>M. Filippi (Milan, IT)</i>	
14.15	MRI and the diagnosis of MS: from MAGNIMS 2016 to the 2017 revision of the McDonald criteria <i>M. Filippi (Milan, IT)</i>	
14.45	Application of MRI diagnostic criteria in clinical practice <i>M. Tintoré (Barcelona, ES)</i>	
15.15	MRI and multiple sclerosis misdiagnosis and differential diagnosis <i>F. Barkhof (London, UK)</i>	
<hr/>		

14.15 – 15.45	Educational Session 21: Symptomatic treatment of MS: how to manage fatigue and gait dysfunction? (RIMS) Level: Basic Chairs: <i>J. Kesselring (Valens, CH)</i> <i>V. de Groot (Amsterdam, NL)</i>	Hall E
14.15	Overview <i>J. Kesselring (Valens, CH)</i>	
14.45	Exercise of gait therapy <i>P. Feys (Hasselt, BE)</i>	
15.15	Pharmacological and non-pharmacological treatment of fatigue <i>V. de Groot (Amsterdam, NL)</i>	
<hr/>		
16.15 – 17.15	Case-based Educational Session 22: MOG-Ab phenotype Chairs: <i>M. Weber (Göttingen, DE)</i> <i>T. Derfuss (Basel, CH)</i>	Hall E
16.15	Case 1: The features of anti-MOG antibody-associated CNS demyelination: NMOSD, MS or a novel disease entity? <i>M. Weber (Göttingen, DE)</i>	
16.45	Case 2: Two cases of anti-MOG associated CNS demyelinating disease <i>T. Derfuss (Basel, CH)</i>	

Friday, 12 October 2018

08.30 – 10.00 **Educational Session 23: NMO-spectrum disorders:
current concepts and clinical management** Hall D

Level: Intermediate

Chairs:

F. Paul (Berlin, DE)

J. Palace (Oxford, UK)

08.30 **NMOSD and AQP4-Ab positive disease classification and update on epidemiology and
phenotypic features**
F. Paul (Berlin, DE)

09.00 **MOG antibody disease update and differentiation from MS and AQP4-Ab positive
disease**
K. Fujihara (Sendai, JP)

09.30 **Treatment of NMOSD using case studies**
J. Palace (Oxford, UK)

08.30 – 10.00 **Educational Session 24: The use of stem cells in MS:
where are we and where are we going?** Hall E

Level: Intermediate

Chairs:

D. Karussis (Jerusalem, IS)

A. Uccelli (Genoa, IT)

08.30 **Overview of the rationale and the options of stem cells therapies in MS and review of
the existing clinical experience**
D. Karussis (Jerusalem, IS)

09.00 **Mesenchymal stem cells in MS: possible mechanisms of action and future directions**
A. Uccelli (Genoa, IT)

09.30 **The rationale and the existing clinical data using Hematopoietic stem cells in MS**
P.A. Muraro (London, UK)

10.30 – 12.00	Educational Session 25: MS mimicks: genetic disorders	Hall D
	Level: Basic	
	Chairs: <i>O. Boespflug-Tanguy (Paris, FR)</i> <i>F. Mochel (Paris, FR)</i>	
10.30	Genetic mimicks with acute presentation <i>O. Boespflug-Tanguy (Paris, FR)</i>	
11.00	Genetic mimicks with progressive presentation <i>F. Mochel (Paris, FR)</i>	
11.30	Treatments in genetic mimicks of MS <i>O. Boespflug-Tanguy (Paris, FR)</i> <i>F. Mochel (Paris, FR)</i>	
<hr/>		
10.30 – 12.00	Educational Session 26: From structural and functional connectivity to clinical impairment in multiple sclerosis (MAGNIMS)	Hall E
	Level: Advanced	
	Chairs: <i>M.A. Rocca (Milan, IT)</i> <i>D. Chard (London, UK)</i>	
10.30	Structural connectivity <i>M. Schoonheim (Amsterdam, NL)</i>	
11.00	Functional connectivity <i>M.A. Rocca (Milan, IT)</i>	
11.30	Clinical significance <i>D. Chard (London, UK)</i>	